Physician profile
Stacy E Stahl
NPI 1972849529
$1,923.66
in general payments reported to CMS, 2019-2025
21 companies · $367 in 2025
The $367 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $254 · 2022: $322 · 2023: $800 · 2024: $182 · 2025: $367.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,243 · Education: $106.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,242.68 |
| Education | $105.87 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $482.48 | 2021-2023 | Tezspire, Airsupra, Symbicort |
| Glaxosmithkline, LLC. | $424.93 | 2021-2024 | Nucala, Arexvy, Trelegy Ellipta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $175.33 | 2021-2024 | Ofev, Stiolto Respimat |
| Novartis Pharmaceuticals Corporation | $156.61 | 2022-2025 | |
| Adc Therapeutics America, INC. | $114.97 | 2025 | |
| Lilly USA, LLC | $105.87 | 2025 | |
| Caris Mpi, INC. | $88.88 | 2025 | Mi Cancer Seek |
| Genentech USA, INC. | $40.71 | 2023-2025 | Xolair, Tecentriq |
| Philips North America LLC | $39.97 | 2022-2023 | (8874) Incourage |
| Mylan Specialty L.P. | $33.12 | 2023-2024 | Yupelri |
| Takeda Pharmaceuticals U.S.A., INC. | $31.20 | 2023 | Glassia |
| Baxter Healthcare | $30.62 | 2023 | Hillrom - Vest System Model 105 Home Care |
| Jazz Pharmaceuticals INC. | $28.84 | 2023 | |
| Insmed, INC. | $25.14 | 2023 | Arikayce |
| Grifols USA, LLC | $23.77 | 2023 | Prolastin-C Liquid |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $23.21 | 2025 | Keytruda, Welireg |
| United Therapeutics Corporation | $22.58 | 2022 | |
| Actelion Pharmaceuticals US, INC. | $21.01 | 2023 | Opsumit |
| Genzyme Corporation | $20.61 | 2023 | |
| Regeneron Healthcare Solutions, INC. | $20.58 | 2023 | Dupixent |
| Amgen INC. | $13.23 | 2023 | Tezspire |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stacy Stahl listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.